Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CB-839 plus cabozantinib vs placebo plus cabozantinib in advanced or metastatic clear-cell renal cell carcinoma
2018-000363-91Phase 2Unknown
- Sponsor
- Calithera Biosciences
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in clear cell renal cell carcinoma (ccRCC) comparing CB-839 plus cabozantinib (CB-Cabo) with Placebo plus cabozantinib (Pbo-Cabo) (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
telaglenastatcabozantinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2018-000363-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000363-91.